Ge Healthcare Limited

Ge Healthcare As

Kidde IP Holdings Limited

Ge Healthcare Limited Company

General Electric Company

Julian Grigg

Torgrim Engell

Dimitrios Mantzilas

Nigel John Osborn

Imtiaz Ahmed Khan

Dag M Evje

Jonathan Robert Shales

Alan Peter Clarke

Alexander Jackson

Anthony Wilson

Graeme McRobbie

Knut Richard Dyrstad

Dirk-Jan In't Veld

Ingvil Gausemel

Ian M Newington

Matthias Eberhard Glaser

Duncan George Wynn

Steven Michael Fairway

Torild Wickstrom

Eric Horn

Lill Torild Wickstrom

Gareth Edwin Smith

Johanthan R Shales

Alan P Clarke

Graeme Mcrobbie

Hendrik Petrus Engelbrecht

Dirk In't Veld

David Alko Golden

Szilárd Németh

The present invention provides a method for the synthesis of an injectable composition comprising a [F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method of purification carried out by means of solid phase extraction (SPE) alone.

Solid phase purification

A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

Method for removing acetaldehyde

The present invention provides a method for the synthesis of an injectable composition comprising a [F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises a method of radiosynthesis that permits a more facile purification using solid phase extraction (SPE).

Stabilized radiolabelling reaction

The present invention relates to calibration and normalization systems and methods for ensuring the quality of radiopharmaceuticals during the synthesis thereof, such as radiopharmaceuticals used in Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT).

Method of operating an automated radiopharmaceutical synthesizer

The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to automated methods for the preparation and purification ofF-labelled tau imaging radiotracers. Also provided are interchangeable cassettes useful in the methods, and the use of automated synthesizers and cassettes in the methods.

Radiolabelling method

Methods and devices for directing a waste fluid from a radiopharmaceutical synthesis system to a waste vessel are provided. In one example, the method includes serially connecting a primary waste vessel to a secondary waste vessel with a fluid conduit, including a waste valve connected to the fluid conduit extending between the primary waste vessel and secondary waste vessel; opening the waste valve so as to allow fluid communication between cavities of the primary and secondary waste vessels; drawing a low pressure in both waste vessels; closing the waste valve so as to fluidically isolate the secondary waste vessel from the primary waste vessel, discharging the waste fluid through a pump valve into the primary waste vessel, and opening the waste valve to evacuate the waste fluid from the primary waste vessel into the secondary waste vessel.

Methods and systems for emptying a waste vessel

The present invention relates to a method for improving stability of non fluoridated sugar derivatives, and in particular glucose derivatives such as 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-&#xdf;-D-mannopyranose which are used as precursors for production of radiofluoridated sugar derivatives for use in in vivo imaging procedures such as positron emission tomography (PET). The method comprises storing the non fluoridated sugar derivative in an organic solvent. The resultant formulations of the non fluoridated sugar derivative and cassettes for automated synthesis apparatus comprising the same are also claimed.

Stabilisation of radiopharmaceutical precursors

The present invention relates to improved radiotracer imaging agent compositions, which comprisesF-labelled biological targeting moieties, wherein impurities which affect imaging in vivo are identified and suppressed. Also provided are radiopharmaceuticals comprising said improved compositions, together with radiofluorinated aldehyde compositions useful in preparing said radiotracer compositions. The invention also includes methods of imaging and/or diagnosis using the radiopharmaceutical compositions described.

Radiotracer compositions

The present invention relates to a method for improving stability of non fluoridated sugar derivatives, and in particular glucose derivatives such as 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-&#x3b2;-D-mannopyranose which are used as precursors for production of radiofluoridated sugar derivatives for use in in vivo imaging procedures such as positron emission tomography (PET). The method comprises storing the non fluoridated sugar derivative in an organic solvent. The resultant formulations of the non fluoridated sugar derivative and cassettes for automated synthesis apparatus comprising the same are also claimed.

Calibration and normalization systems and methods for radiopharmaceutical synthesizers

The invention describes a method for stripping alumina which is particularly suitable for removal of fluoride from alumina and comprises washing said alumina with an aqueous acid or alkali at elevated temperature. The method may be used for removal of unreacted radiofluoride such as [F]fluoride from alumina following a radiofluorination reaction. Automated synthesis apparatus and cassettes therefor, which are adapted to perform the method are also claimed.

Stripping method

Growing community of inventors

Amersham, United Kingdom

Julian Grigg